CTS On The Rebound?
Executive Summary
In the battle for the minimally-invasive cardiac surgery market, CTS has long been seen as second fiddle to HeartPort. But while HeartPort has struggled, CTS has been growing nicely. With nearly 50% of the minimally-invasive cardiac surgery market, CTS is now the market leader and watching competitors fall by the wayside. Now the trick is convincing investors.
You may also be interested in...
Cardica: Rebuilding the Cardiac Surgery Market
The predicted expansion of beating-heart and minimally-invasive cardiac surgery never materialized, a result, some say, of the lack of safe and effective automated anastomotic tools. Cardica believes it has the answer that can at long last grow this market.
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Need a specific report? 1000+ reports available
Buy Reports